Boston Scientific snags Bayer’s peripheral unit for $415M

Candace Stuart | | Cardiovascular Business | Vascular & Endovascular

Boston Scientific will buy the interventional device division at Bayer AG for $415 million. The acquisition will let Boston Scientific widen its portfolio of technologies used to treat coronary and peripheral vascular disease.

The sale will give Boston Scientific rights to AngioJet, a thrombectomy device, JetStream, an atherectomy technology, and Fetch 2, an aspiration catheter. Bayer Interventional reported $120 million in sales in the atherectomy and thrombectomy markets in 2013.

Berlin-based Bayer HealthCare CEO Olivier Brandicourt, MD, said in a release that the transaction would allow Bayer to concentrate on its radiology and diabetes divisions. Alan Main, president of Bayer HealthCare's Medical Care Division, called the addition of AngioJet, Jetstream and Fetch2 “a positive step for the long-term sustainability of these products.”

Boston Scientific is based in Natick, Mass. Bayer Interventional, which employs 350 people, is in Coon Rapids, Minn. The sale is expected to be completed in the second half of 2014.

Candace Stuart, Contributor

Related Content

‘Fundamental for all patients’: Exploring the benefits of palliative care for stroke survivors
Advancing AI for vascular surgery will require a commitment to data integrity
Industry concerns over paclitaxel-coated devices may have put PAD patients at risk
Genetic predisposition to depression increases CVD risk in women, but not men
Clopidogrel vs. aspirin: Tracking the chronic maintenance period after PCI for different risk groups
IVUS-guided PCI reduces risks in patients with diabetes

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.